TIZANIDINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Tizanidine Hydrochloride, and what generic alternatives are available?

Tizanidine Hydrochloride is a drug marketed by Alembic, Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Jubilant Generics, Novast Labs, Ph Health, Pharmobedient, Rubicon Research, Senores Pharms, Zydus Pharms, Ani Pharms, Apotex, Aurobindo Pharma Usa, Cadila, Chartwell Rx, Dr Reddys Labs Inc, Epic Pharma Llc, Oxford Pharms, Rising, Sun Pharm Inds Inc, and Unichem Labs Ltd. and is included in twenty-nine NDAs.

The generic ingredient in TIZANIDINE HYDROCHLORIDE is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tizanidine Hydrochloride

A generic version of TIZANIDINE HYDROCHLORIDE was approved as tizanidine hydrochloride by DR REDDYS LABS INC on July 3^rd, 2002.

Summary for TIZANIDINE HYDROCHLORIDE

US Patents:	0
Applicants:	23
NDAs:	29
Finished Product Suppliers / Packagers:	48
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	1,419
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIZANIDINE HYDROCHLORIDE
What excipients (inactive ingredients) are in TIZANIDINE HYDROCHLORIDE?	TIZANIDINE HYDROCHLORIDE excipients list
DailyMed Link:	TIZANIDINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for TIZANIDINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Uak University	NA
Mansoura University	NA
Kafrelsheikh University	NA

See all TIZANIDINE HYDROCHLORIDE clinical trials

Pharmacology for TIZANIDINE HYDROCHLORIDE

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

Anatomical Therapeutic Chemical (ATC) Classes for TIZANIDINE HYDROCHLORIDE

M03BX	Other centrally acting agents
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for TIZANIDINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZANAFLEX	Capsules	tizanidine hydrochloride	2 mg, 4 mg and 6 mg	021447	1	2007-08-10

US Patents and Regulatory Information for TIZANIDINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	TABLET;ORAL	076321-001	Sep 30, 2004		DISCN	No	No
Senores Pharms	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	CAPSULE;ORAL	213365-001	May 13, 2024	AB	RX	No	No
Aurobindo Pharma Usa	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	TABLET;ORAL	076282-001	Dec 16, 2003		DISCN	No	No

Market Dynamics and Financial Trajectory of Tizanidine Hydrochloride

Last updated: February 19, 2026

Tizanidine hydrochloride (brand names include Zanaflex) is a centrally acting muscle relaxant prescribed for spasticity management. Its market position, growth prospects, and competitive landscape depend on regulatory status, patent life, clinical indications, and pricing trends.

Regulatory and Patent Landscape

Regulatory Approval:

• Approved by the U.S. FDA in 1996 for short-term management of spasticity.
• Global approvals vary, with European Medicines Agency (EMA) approval in 1996 as well.

Patent Status and Exclusivity:

• Key patents expired around early 2010s, opening market for generics.
• No recent patent extensions or new formulations received by branded manufacturers.

Implication:
Patent expiration led to increased generic competition, exerting downward pressure on prices and margins.

Market Size and Growth Drivers

Global Market Value (2022):

• Estimated at approximately $150 million, with projections exceeding $200 million by 2027.
• Compound annual growth rate (CAGR): about 5% (2022–2027).

Key Drivers:

• The prevalence of multiple sclerosis, spinal cord injury, and stroke-related spasticity.
• Growing geriatric population with increased spasticity comorbidities.
• Off-label use for other muscle spasm conditions.

Regional Trends:

• U.S. constitutes 60% of sales, driven by high diagnosis rates of neurological conditions.
• Europe accounts for approximately 25%.
• Asia-Pacific shows initial growth due to rising healthcare infrastructure.

Competitive Landscape

Main Players:

• Teva Pharmaceuticals: Pioneer in generic tizanidine.
• Mitsubishi Tanabe Pharma: Marketed branded Zanaflex in some regions.

Market Penetration:

• Generics hold over 80% market share in the U.S. since patent expiry.
• Price erosion intensifies, with average wholesale prices (AWP) dropping by about 20-30% post-patent expiry.

Pricing Trends:

• Brand Zanaflex retail price (~$400 for a 30-day supply).
• Generics retail price (~$120–$180 for the same).
• Cost reductions align with generic market expansion.

Revenue and Profitability Trends

Branded Product:

• Peak sales in 2007 estimated at ~$300 million.
• Rapid decline after patent expiration due to generic entry.

Generics:

• Revenue primarily driven by high-volume, low-margin sales.
• Low single-digit profit margins (~5%), impacted by increased manufacturing scale and competitive pricing.

Financial Outlook:

• Post-2020 focus on formulations for specific patient populations (e.g., extended-release versions).
• Potential for niche growth through combination therapies.

Development and Regulatory Pipeline

Current Status:

• No major new formulations or pending patents.
• Limited pipeline activity; pharmaceutical companies prioritize newer agents for spasticity.

Research Trends:

• Investigations into combination therapies for spasticity management.
• Potential off-label uses may bootstrap market activity in specific conditions.

Future Market Outlook

• The generic segment will dominate, but growth stagnates without new formulations.
• Innovations in delivery methods or combination therapy could revitalize interest.
• Increasing healthcare budgets and aging populations support continued demand.

Risks:

• Competition from newer spasticity agents (e.g., baclofen pumps, tizanidine alternatives).
• Regulatory constraints on off-label use and reimbursement pressures.

Summary Table

Aspect	Details	Implication
Market size (2022)	~$150 million	Steady growth potential
CAGR (2022–2027)	5%	Moderate market expansion
Patent expiry	Early 2010s	Surge in generics, price declines
Major players	Teva, Mitsubishi	High generic market share
Regional markets	U.S., Europe, APAC	Geographic growth opportunities
Pricing	Branded ~$400/month, Generic ~$150/month	Significant cost savings post-generic entry
Innovation pipeline	Limited	Market stability in current formulations

Key Takeaways

• Tizanidine hydrochloride's market shifted post-patent expiration, with generics dominating sales.
• The market grows modestly, driven by neurological conditions and aging populations.
• Price competition and low margins characterize the generic segment, suppressing revenue growth.
• No significant pipeline developments or patent protections diminish future upside.
• Potential exists in formulation innovation, but barriers include regulatory and reimbursement challenges.

FAQs

1. How has patent expiration affected tizanidine hydrochloride's market?
Patent expiration led to an increase in generic versions, reducing prices and margins, with generics capturing over 80% of sales in the U.S.

2. What are the main competitors in this market?
Teva Pharmaceuticals and Mitsubishi Tanabe Pharma dominate the generic space, with branded Zanaflex having limited market share post-patent expiry.

3. What is the outlook for future revenue?
Market growth remains modest at around 5% CAGR through 2027, primarily driven by increased prevalence of neurological disorders; no major new formulations are expected.

4. Are there any recent innovations in tizanidine formulations?
Research is limited; current strategies focus on formulations for specific populations, with no significant pipeline activity.

5. What risks could impact future market stability?
Emerging therapies, regulatory restrictions, and reimbursement policies pose risks; competition from newer agents may also limit growth.

---

References

1. U.S. Food and Drug Administration (FDA). (1996). Approval letter for tizanidine hydrochloride.
2. Allied Market Research. (2022). Spasticity management market forecast.
3. IMS Health. (2022). Prescription data and pricing trends for neuromuscular drugs.
4. European Medicines Agency (EMA). (1996). Marketing authorization for tizanidine.
5. IQVIA. (2022). Global drug sales and market share analysis.